FDA Approves MORPHINE SULFATE — Actavis Pharma, Inc.

Actavis Pharma, Inc. has received FDA approval for its Abbreviated New Drug Application (ANDA) for morphine sulfate oral solid dosage forms, potentially broadening access to this critical pain management therapy. The approval empowers the company to compete head-to-head with brand-name formulations, which could exert pressure on the existing market share held by established manufacturers.